Regeneron’s stock climbs 4% as analyst look past earnings miss to focus on pipeline

Regeneron Pharmaceuticals’ stock reversed early losses to trade higher on Thursday, as analysts looked beyond a first-quarter earnings miss to focus on some of the biotech’s pipeline products.